ENTEX T OTC
Generic Name and Formulations:
Guaifenesin 375mg; pseudoephedrine HCl 60mg; per scored tab.
Indications for ENTEX T:
Nasal, sinus and chest congestion. Cough.
1 tab every 4–6hrs; max 4 tabs/24hrs.
<6yrs: not recommended. 6–12yrs: ½ tab every 4–6hrs; max 4 tabs/24hrs.
During or within 14 days of MAOIs.
Cardiovascular disease. Hypertension. Thyroid disease. Diabetes. Asthma. GI or GU obstruction. Lower respiratory disorders. Pregnancy. Nursing mothers.
Expectorant + sympathomimetic.
See Contraindications. Hypertensive crisis with MAOIs. β-blockers increase pressor effects of sympathomimetics. Antagonizes antihypertensives.
Nervousness, dizziness, insomnia.
Endocrinology Advisor Articles
- Long-Term Efficacy and Safety of Dapagliflozin for Type 1 Diabetes
- Measuring Time in Range During CGM May Be Useful Outcome Metric for Clinical Trials
- HbA1c Variability in General Population Increases Risk for Cardiovascular Events, All-Cause Mortality
- Safety and Effectiveness of the Most Common Bariatric Procedures Examined
- AHA, ADA Announce Joint Education Initiative to Reduce CVD Deaths in T2D
- High Circulating Prolactin Concentrations May Lower Risk for Type 2 Diabetes
- Online Tool Helps Patients With Advance Care Planning
- Dapagliflozin Lowers Heart Failure Hospitalization Rates in High-Risk Patients With Diabetes
- Direct-Acting Antiviral Therapy Reduced Risk for Incident T2D in Patients With Hepatitis C Infection
- Technological Breakthroughs in Medicine Move Physician-Patient Interactions From The Computer Screen Back to the Exam Room